Kathleen Tregoning - Net Worth and Insider Trading
Kathleen Tregoning Net Worth
The estimated net worth of Kathleen Tregoning is at least $337,919 dollars as of 2024-11-10. Kathleen Tregoning is the See Remarks of Cerevel Therapeutics Holdings Inc and owns about 7,516 shares of Cerevel Therapeutics Holdings Inc (CERE) stock worth over $337,919. Details can be seen in Kathleen Tregoning's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kathleen Tregoning has not made any transactions after 2023-12-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Kathleen Tregoning
Kathleen Tregoning Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kathleen Tregoning owns 2 companies in total, including Spero Therapeutics Inc (SPRO) , and Cerevel Therapeutics Holdings Inc (CERE) .
Click here to see the complete history of Kathleen Tregoning’s form 4 insider trades.
Insider Ownership Summary of Kathleen Tregoning
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
SPRO | Spero Therapeutics Inc | 2021-10-11 | director |
CERE | Cerevel Therapeutics Holdings Inc | 2023-12-20 | See Remarks |
Kathleen Tregoning Latest Holdings Summary
Kathleen Tregoning currently owns a total of 1 stock. Kathleen Tregoning owns 7,516 shares of Cerevel Therapeutics Holdings Inc (CERE) as of December 20, 2023, with a value of $337,919.
Latest Holdings of Kathleen Tregoning
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CERE | Cerevel Therapeutics Holdings Inc | 2023-12-20 | 7,516 | 44.96 | 337,919 |
Holding Weightings of Kathleen Tregoning
Kathleen Tregoning Form 4 Trading Tracker
According to the SEC Form 4 filings, Kathleen Tregoning has made a total of 1 transactions in Cerevel Therapeutics Holdings Inc (CERE) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Cerevel Therapeutics Holdings Inc is the sale of 6,288 shares on December 20, 2023, which brought Kathleen Tregoning around $260,449.
Insider Trading History of Kathleen Tregoning
- 1
Kathleen Tregoning Trading Performance
Kathleen Tregoning Ownership Network
Ownership Network List of Kathleen Tregoning
Ownership Network Relation of Kathleen Tregoning
Kathleen Tregoning Owned Company Details
What does Spero Therapeutics Inc do?
Who are the key executives at Spero Therapeutics Inc?
Kathleen Tregoning is the director of Spero Therapeutics Inc. Other key executives at Spero Therapeutics Inc include Chief Development Officer Timothy Keutzer , director & See Remarks Ankit Mahadevia , and Chief Financial Officer Sath Shukla .
Spero Therapeutics Inc (SPRO) Insider Trades Summary
Over the past 18 months, Kathleen Tregoning made no insider transaction in Spero Therapeutics Inc (SPRO). Other recent insider transactions involving Spero Therapeutics Inc (SPRO) include a net sale of 117,209 shares made by Sath Shukla , a net sale of 78,747 shares made by Ankit Mahadevia , and a net sale of 35,038 shares made by Timothy Keutzer .
In summary, during the past 3 months, insiders sold 10,882 shares of Spero Therapeutics Inc (SPRO) in total and bought 0 shares, with a net sale of 10,882 shares. During the past 18 months, 331,325 shares of Spero Therapeutics Inc (SPRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 331,325 shares.
Spero Therapeutics Inc (SPRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Spero Therapeutics Inc Insider Transactions
Kathleen Tregoning Mailing Address
Above is the net worth, insider trading, and ownership report for Kathleen Tregoning. You might contact Kathleen Tregoning via mailing address: C/o Cerevel Therapeutics Holdings, Inc., 131 Dartmouth Street Suite 502, Boston Ma 02116.